(no title)
paviva | 4 years ago
The fragility index is essentially a repackaged p-value, and serves only to introduce even more confusion on the top of this already often misunderstood metric. See very good discussion here: https://academic.oup.com/eurheartj/article/38/5/346/2422087
Also, trials are generally designed to recruit the minimal number of patients we can get away with, and this is done for good reason (cost, feasibility, and the ethical concern of "using" the lowest possible number of human beings, while allowing any beneficial treatment to benefit the most as soon as possible). If someone's then pointing out that this trial is "fragile" -- well, yes, it was designed so in advance! Would you propose to expose 100 more patients to an inferior treatment just to improve your fragility index?
esyir|4 years ago
So, to re-answer your question
>Would you propose to expose 100 more patients to an inferior treatment just to improve your fragility index
Absolutely, especially if the alternative is exposing a million more patients to a different, more expensive inferior treatment because the statistical analysis was garbage.
paviva|4 years ago
Nobody should interpret clinical studies in isolation; they only have meaning in a "qualitative" Bayesian framework which integrates physiological plausibility, other available trials, and risk/benefit ratio. The fragility index only muddies waters, as clinicians misinterpret it even more frequently than the much maligned p-value, all while not delivering any more information than the p-value itself.